Spruce Biosciences, Inc.2024财年第二财季实现净利润-9.18百万美元，同比增加28.39%

自选股智能写手08-16

8月16日，Spruce Biosciences, Inc.（SPRB.US）公布财报，公告显示公司2024财年第二财季净利润为-9.18百万美元，同比增加28.39%；其中营业收入为1.61百万美元，同比减少25.81%，每股基本收益为-0.22美元。从资产负债表来看，Spruce Biosciences, Inc.（SPRB.US）总负债16.35百万美元，其中短期债务1.89百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2459906472?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-16 00:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2459906472","market":"us","top_or_hot":-1,"title":"Spruce Biosciences, Inc.2024财年第二财季实现净利润-9.18百万美元，同比增加28.39%","media":"自选股智能写手","content":"<div>\n<p>8月16日，Spruce Biosciences, Inc.（SPRB.US）公布财报，公告显示公司2024财年第二财季净利润为-9.18百万美元，同比增加28.39%；其中营业收入为1.61百万美元，同比减少25.81%，每股基本收益为-0.22美元。从资产负债表来看，Spruce Biosciences, Inc.（SPRB.US）总负债16.35百万美元，其中短期债务1.89百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816000350959be73d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spruce Biosciences, Inc.2024财年第二财季实现净利润-9.18百万美元，同比增加28.39%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpruce Biosciences, Inc.2024财年第二财季实现净利润-9.18百万美元，同比增加28.39%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-16 00:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816000350959be73d&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月16日，Spruce Biosciences, Inc.（SPRB.US）公布财报，公告显示公司2024财年第二财季净利润为-9.18百万美元，同比增加28.39%；其中营业收入为1.61百万美元，同比减少25.81%，每股基本收益为-0.22美元。从资产负债表来看，Spruce Biosciences, Inc.（SPRB.US）总负债16.35百万美元，其中短期债务1.89百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816000350959be73d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SPRB","symbol_name":"Spruce Biosciences, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816000350959be73d&s=b","article_id":"2459906472","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240816000350959be73d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2459906472","pubTimestamp":1723737823,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月16日，Spruce Biosciences, Inc.公布财报，公告显示公司2024财年第二财季净利润为-9.18百万美元，同比增加28.39%；其中营业收入为1.61百万美元，同比减少25.81%，每股基本收益为-0.22美元。从资产负债表来看，Spruce Biosciences, Inc.总负债16.35百万美元，其中短期债务1.89百万美元，资产负债比为4.62，流动比率为5.18。机构评级：截至2024年8月16日，当前有4家机构对Spruce Biosciences, Inc.目标价做出预测，其中目标均价为2.50美元，其中最低目标价为2.00美元，最高目标价为3.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"SPRB":"Spruce Biosciences, Inc."},"translate_title":"Spruce Biosciences, Inc. achieved net profit of-US $9.18 million in the second fiscal quarter of fiscal year 2024, a year-on-year increase of 28.39%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRB":1},"content_text":"8月16日，Spruce Biosciences, Inc.（SPRB.US）公布财报，公告显示公司2024财年第二财季净利润为-9.18百万美元，同比增加28.39%；其中营业收入为1.61百万美元，同比减少25.81%，每股基本收益为-0.22美元。从资产负债表来看，Spruce Biosciences, Inc.（SPRB.US）总负债16.35百万美元，其中短期债务1.89百万美元，资产负债比为4.62，流动比率为5.18。机构评级：截至2024年8月16日，当前有4家机构对Spruce Biosciences, Inc.目标价做出预测，其中目标均价为2.50美元，其中最低目标价为2.00美元，最高目标价为3.00美元。公司简介：Spruce Biosciences Inc 是一家后期生物制药公司，专注于开发和商业化针对未满足医疗需求的罕见内分泌疾病的新疗法。 该公司最初正在开发其全资候选产品 tildacerfont，作为潜在的第一个非甾体疗法，为患有经典先天性肾上腺增生症（ CAH ）的患者提供显着改善的疾病控制并减轻类固醇负担。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459906472"}